Pienta KJ - Search Results

1

Rapid ("warm") autopsy study for procurement of metastatic prostate cancer.

Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, Pienta KJ. Rubin MA, et al. Among authors: pienta kj. Clin Cancer Res. 2000 Mar;6(3):1038-45. Clin Cancer Res. 2000. PMID: 10741732

2

Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide.

Pienta KJ, Nguyen NM, Lehr JE. Pienta KJ, et al. Cancer Res. 1993 Jan 15;53(2):224-6. Cancer Res. 1993. PMID: 7678070

3

The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer.

Smith DC, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Urol Clin North Am. 1997 May;24(2):433-7. doi: 10.1016/s0094-0143(05)70390-6. Urol Clin North Am. 1997. PMID: 9126241

4

A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.

Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC. Pienta KJ, et al. Urology. 1997 Sep;50(3):401-6; discussion 406-7. doi: 10.1016/S0090-4295(97)00228-8. Urology. 1997. PMID: 9301705 Clinical Trial.

5

Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.

Pienta KJ, Smith DC. Pienta KJ, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-72-S15-77. Semin Oncol. 1997. PMID: 9346227 Clinical Trial.

6

The effect of castanospermine on the metastatic properties of prostate cancer cells.

Yee CS, Schwab ED, Lehr JE, Quigley M, Pienta KJ. Yee CS, et al. Among authors: pienta kj. Anticancer Res. 1997 Sep-Oct;17(5A):3659-63. Anticancer Res. 1997. PMID: 9413219

7

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

Smith DC, Dunn RL, Strawderman MS, Pienta KJ. Smith DC, et al. Among authors: pienta kj. J Clin Oncol. 1998 May;16(5):1835-43. doi: 10.1200/JCO.1998.16.5.1835. J Clin Oncol. 1998. PMID: 9586898 Clinical Trial.

8

The effect of amiloride on the metastatic properties of prostate cancer in the Dunning rat model.

Pilat MJ, Lehr JE, Quigley MM, Pienta KJ. Pilat MJ, et al. Among authors: pienta kj. Oncol Rep. 1998 Jul-Aug;5(4):889-92. doi: 10.3892/or.5.4.889. Oncol Rep. 1998. PMID: 9625839

9

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. Smith DC, et al. Among authors: pienta kj. Urology. 1998 Aug;52(2):257-60. doi: 10.1016/s0090-4295(98)00173-3. Urology. 1998. PMID: 9697791 Clinical Trial.

10

Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.

Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Greenberg NM, Zeng Z, Sanda MG. Hsu CX, et al. Among authors: pienta kj. J Urol. 1998 Oct;160(4):1500-5. J Urol. 1998. PMID: 9751403

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

650 results

Search Page

Filters